6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 35 (1), 974-992
- https://doi.org/10.1080/14756366.2020.1747449
Abstract
Aiming to deepen the structure–activity relationships of the two P-glycoprotein (P-gp) modulators elacridar and tariquidar, a new series of amide and ester derivatives carrying a 6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline scaffold linked to different methoxy-substituted aryl moieties were synthesised. The obtained compounds were evaluated for their P-gp interaction profile and selectivity towards the two other ABC transporters, multidrug-resistance-associated protein-1 and breast cancer resistance protein, showing to be very active and selective versus P-gp. Two amide derivatives, displaying the best P-gp activity, were tested in co-administration with the antineoplastic drug doxorubicin in different cancer cell lines, showing a significant sensitising activity towards doxorubicin. The investigation on the chemical stability of the derivatives towards spontaneous or enzymatic hydrolysis, showed that amides are stable in both models while some ester compounds were hydrolysed in human plasma. This study allowed us to identify two chemosensitizers that behave as non-transported substrates and are characterised by different selectivity profiles. Graphical AbstractKeywords
Funding Information
- University of Florence (RICATEN17, RICATEN18)
- MIUR-FIRB (RBFR12SOQ1_003, 004)
- Italian Association for Cancer Research (IG21408)
This publication has 56 references indexed in Scilit:
- Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by TariquidarPLOS ONE, 2013
- Cu(II) bromide catalyzed oxidation of aldehydes and alcoholsApplied Organometallic Chemistry, 2011
- A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical CancerClinical Cancer Research, 2011
- Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999Blood, 2010
- P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Blood, 2010
- Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal CancerJournal of Clinical Oncology, 2008
- In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous SystemDrug Metabolism and Disposition, 2007
- Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defenseToxicology and Applied Pharmacology, 2005
- Diphenylcyclohexylamine derivatives as new potent multidrug resistance (MDR) modulatorsBioorganic & Medicinal Chemistry, 2005
- Biosynthesis of the Cinchona Alkaloids. I. The Incorporation of Tryptophan into QuinineJournal of the American Chemical Society, 1962